Modelled Public Health Impact of Introducing Adjuvanted Recombinant Zoster Vaccine into the UK National Immunisation Programme
Abstract Introduction In 2023, recombinant zoster vaccine (RZV) replaced zoster vaccine live (ZVL) vaccine in the UK National Immunisation Programme (NIP) for prevention of herpes zoster (HZ). The vaccination age was reduced from 70 to 65 years, with a subsequent planned reduction to 60 years. This...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2024-11-01
|
| Series: | Infectious Diseases and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40121-024-01073-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571420211675136 |
|---|---|
| author | Manjit Hunjan Desmond Curran Alen Marijam Yasmeeta Vekria Nikolaos Giannelos |
| author_facet | Manjit Hunjan Desmond Curran Alen Marijam Yasmeeta Vekria Nikolaos Giannelos |
| author_sort | Manjit Hunjan |
| collection | DOAJ |
| description | Abstract Introduction In 2023, recombinant zoster vaccine (RZV) replaced zoster vaccine live (ZVL) vaccine in the UK National Immunisation Programme (NIP) for prevention of herpes zoster (HZ). The vaccination age was reduced from 70 to 65 years, with a subsequent planned reduction to 60 years. This modelling study aimed to evaluate the public health impact (PHI) of RZV vaccination in the 70 years of age (YOA) population and in younger individuals 65 and 60 YOA. Methods PHI was evaluated from a National Health Service perspective, as cases of HZ, post-herpetic neuralgia (PHN), non-PHN complications and deaths, hospitalisations, and general practitioner (GP) visits avoided using a multicohort Markov model. Three scenarios (RZV vs. no vaccination, ZVL vs. no vaccination, and RZV vs. ZVL) were explored for each age group using population estimates from the UK Office for National Statistics, i.e. 70 YOA (n = 649,822), 65 YOA (n = 760,578) and 60 YOA (n = 849,501). Results Modelled outcomes in 70 YOA individuals estimated that RZV vaccination would avoid 32,894 cases of HZ and 5915 cases of PHN compared with no vaccination and 26,954 HZ and 3218 PHN cases compared with ZVL. Compared with no vaccination, 2264 fewer hospitalisations and 158,549 fewer GP visits were predicted with RZV vaccination. Hospitalisations were predicted to be reduced by 1996 and GP visits by 130,821 for RZV versus ZVL vaccination. In individuals 65 YOA, it was estimated that RZV vaccination would avoid 50,128 HZ cases, 8623 PHN cases, 222,646 GP visits, and 2671 hospitalisations versus no vaccination. In the 60 YOA group, RZV vaccination was predicted to avoid 57,182 HZ cases, 9327 PHN cases, 234,330 GP visits, and 2547 hospitalisations versus no vaccination. Conclusion The recent introduction of RZV into the NIP could substantially reduce HZ disease burden and healthcare resource use in the UK. A graphical abstract is available with this article. Graphical Abstract |
| format | Article |
| id | doaj-art-02655b473eda4c7494acddf349016626 |
| institution | Kabale University |
| issn | 2193-8229 2193-6382 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Infectious Diseases and Therapy |
| spelling | doaj-art-02655b473eda4c7494acddf3490166262025-02-02T12:35:13ZengAdis, Springer HealthcareInfectious Diseases and Therapy2193-82292193-63822024-11-0114110511910.1007/s40121-024-01073-3Modelled Public Health Impact of Introducing Adjuvanted Recombinant Zoster Vaccine into the UK National Immunisation ProgrammeManjit Hunjan0Desmond Curran1Alen Marijam2Yasmeeta Vekria3Nikolaos Giannelos4GSKGSKGSKGSKGSKAbstract Introduction In 2023, recombinant zoster vaccine (RZV) replaced zoster vaccine live (ZVL) vaccine in the UK National Immunisation Programme (NIP) for prevention of herpes zoster (HZ). The vaccination age was reduced from 70 to 65 years, with a subsequent planned reduction to 60 years. This modelling study aimed to evaluate the public health impact (PHI) of RZV vaccination in the 70 years of age (YOA) population and in younger individuals 65 and 60 YOA. Methods PHI was evaluated from a National Health Service perspective, as cases of HZ, post-herpetic neuralgia (PHN), non-PHN complications and deaths, hospitalisations, and general practitioner (GP) visits avoided using a multicohort Markov model. Three scenarios (RZV vs. no vaccination, ZVL vs. no vaccination, and RZV vs. ZVL) were explored for each age group using population estimates from the UK Office for National Statistics, i.e. 70 YOA (n = 649,822), 65 YOA (n = 760,578) and 60 YOA (n = 849,501). Results Modelled outcomes in 70 YOA individuals estimated that RZV vaccination would avoid 32,894 cases of HZ and 5915 cases of PHN compared with no vaccination and 26,954 HZ and 3218 PHN cases compared with ZVL. Compared with no vaccination, 2264 fewer hospitalisations and 158,549 fewer GP visits were predicted with RZV vaccination. Hospitalisations were predicted to be reduced by 1996 and GP visits by 130,821 for RZV versus ZVL vaccination. In individuals 65 YOA, it was estimated that RZV vaccination would avoid 50,128 HZ cases, 8623 PHN cases, 222,646 GP visits, and 2671 hospitalisations versus no vaccination. In the 60 YOA group, RZV vaccination was predicted to avoid 57,182 HZ cases, 9327 PHN cases, 234,330 GP visits, and 2547 hospitalisations versus no vaccination. Conclusion The recent introduction of RZV into the NIP could substantially reduce HZ disease burden and healthcare resource use in the UK. A graphical abstract is available with this article. Graphical Abstracthttps://doi.org/10.1007/s40121-024-01073-3Herpes zosterPost-herpetic neuralgiaVaccinationRecombinant zoster vaccineZoster vaccine liveHealthcare burden |
| spellingShingle | Manjit Hunjan Desmond Curran Alen Marijam Yasmeeta Vekria Nikolaos Giannelos Modelled Public Health Impact of Introducing Adjuvanted Recombinant Zoster Vaccine into the UK National Immunisation Programme Infectious Diseases and Therapy Herpes zoster Post-herpetic neuralgia Vaccination Recombinant zoster vaccine Zoster vaccine live Healthcare burden |
| title | Modelled Public Health Impact of Introducing Adjuvanted Recombinant Zoster Vaccine into the UK National Immunisation Programme |
| title_full | Modelled Public Health Impact of Introducing Adjuvanted Recombinant Zoster Vaccine into the UK National Immunisation Programme |
| title_fullStr | Modelled Public Health Impact of Introducing Adjuvanted Recombinant Zoster Vaccine into the UK National Immunisation Programme |
| title_full_unstemmed | Modelled Public Health Impact of Introducing Adjuvanted Recombinant Zoster Vaccine into the UK National Immunisation Programme |
| title_short | Modelled Public Health Impact of Introducing Adjuvanted Recombinant Zoster Vaccine into the UK National Immunisation Programme |
| title_sort | modelled public health impact of introducing adjuvanted recombinant zoster vaccine into the uk national immunisation programme |
| topic | Herpes zoster Post-herpetic neuralgia Vaccination Recombinant zoster vaccine Zoster vaccine live Healthcare burden |
| url | https://doi.org/10.1007/s40121-024-01073-3 |
| work_keys_str_mv | AT manjithunjan modelledpublichealthimpactofintroducingadjuvantedrecombinantzostervaccineintotheuknationalimmunisationprogramme AT desmondcurran modelledpublichealthimpactofintroducingadjuvantedrecombinantzostervaccineintotheuknationalimmunisationprogramme AT alenmarijam modelledpublichealthimpactofintroducingadjuvantedrecombinantzostervaccineintotheuknationalimmunisationprogramme AT yasmeetavekria modelledpublichealthimpactofintroducingadjuvantedrecombinantzostervaccineintotheuknationalimmunisationprogramme AT nikolaosgiannelos modelledpublichealthimpactofintroducingadjuvantedrecombinantzostervaccineintotheuknationalimmunisationprogramme |